StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Up 82.6 %

Shares of TherapeuticsMD stock opened at $1.57 on Thursday. TherapeuticsMD has a 1-year low of $0.70 and a 1-year high of $2.75. The firm’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.58.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.